Sorrento therapeutics

Beleggen in aandelen beurs New York, Dow Jones, Nasdaq-100 en S&P500



alwaysright
Forum veteraan
Forum veteraan
Berichten: 1025
Lid geworden op: 10 mei 2013 19:25
waarderingen: 459

Re: Sorrento therapeutics

Bericht door alwaysright »

believer schreef:
04 jun 2021 12:09
alwaysright schreef:
04 jun 2021 11:46
Heb ik wat gemist??
Als ik het Yahoo forum bekijk dan krijg ik de indruk dat die Covi-Stix in Mexico al op de markt is.
Wie heeft duidelijkheid?
Uit het persbericht:

Sorrento has initiated importation and commercial roll-out activities for Mexico and expects the product to be commercially available in-market within weeks.
Ja,duidelijk..ik had dat ook gelezen.
Dan zijn die Amerikanen weer eens over enthousiast :D
Bedankt voor deze reminder :up:



believer
Forum elite
Forum elite
Berichten: 5471
Lid geworden op: 14 jan 2015 17:30
waarderingen: 4657

Re: Sorrento therapeutics

Bericht door believer »

ancaoli liked last!

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 315
Lid geworden op: 28 mar 2019 23:43
waarderingen: 166

Re: Sorrento therapeutics

Bericht door MONEYCAT »

En plots hoge volumes en steile opgang inééns naar 8.40 ! :think: :clap:

ancaoli
Forum elite
Forum elite
Berichten: 2200
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1236

Re: Sorrento therapeutics

Bericht door ancaoli »

Yep, nog nieuws!

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer
believer liked last!
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

MONEYCAT
Forum actieveling
Forum actieveling
Berichten: 315
Lid geworden op: 28 mar 2019 23:43
waarderingen: 166

Re: Sorrento therapeutics

Bericht door MONEYCAT »

ancaoli schreef:
04 jun 2021 19:15
Yep, nog nieuws!

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer
Het begint PR's te regenen en onze vulkaan geraakt stilaan vol met kolkende lava : de uitbarsting kan nu toch niet lang meer uitblijven, als je het mij vraagt ! :think: :up:

ancaoli
Forum elite
Forum elite
Berichten: 2200
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1236

Re: Sorrento therapeutics

Bericht door ancaoli »

Moet de echte PR nog lezen maar lijkt mij eerder klein nieuws...
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

dochter123
Forum veteraan
Forum veteraan
Berichten: 1196
Lid geworden op: 18 apr 2012 10:16
waarderingen: 626

Re: Sorrento therapeutics

Bericht door dochter123 »

believer liked last!

ancaoli
Forum elite
Forum elite
Berichten: 2200
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1236

Re: Sorrento therapeutics

Bericht door ancaoli »

ancaoli schreef:
04 jun 2021 19:27
Moet de echte PR nog lezen maar lijkt mij eerder klein nieuws...
Toch wel interessante samenwerking. Long term opp! Liever samenwerkingen dan alles zelf en alleen proberen te regelen. Extra pijl aan de boog!

News Release

Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapid

June 4, 2021 at 1:00 PM EDT
Download PDF
SAN DIEGO and STOCKHOLM, Sweden, June 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the Company has entered into an additional collaborative agreement with NextGenNK Competence Center-associated research groups at the Department of Medicine, Huddinge, Karolinska Institutet (“KI”) in Stockholm, Sweden, aimed at producing novel cell-based therapeutics using natural killer (“NK”) cells derived from induced pluripotent stem cells (“iPSCs”). Sorrento and KI are collaborative partners in the Competence Center for the development of next-generation NK cell-based cancer immunotherapies (“NextGenNK”) coordinated by KI.

Under the agreement, Sorrento will provide know-how in the core chimeric antigen receptor (“CAR”) and dimeric antigen receptor (“DAR”) technologies and support the collaborative effort to develop new CAR-NK and DAR-NK candidates, as well as fund the translational validation of the technologies. Multiple product candidates will be developed and tested in the initial phase of the planned work, with the goal that the candidate products will qualify for further human clinical trials.

The foundational Sorrento research assets critical to this program are novel proprietary CAR and DAR constructs identified through Sorrento’s proprietary G-MAB™ fully human antibody library and previously validated as determinants of cell-based therapy potency against hematologic and solid tumors.

“It is a privilege to continue and extend our collaborative work with the distinguished KI faculty. We are proud to contribute our technologies to produce new optimized off-the-shelf adoptive NK cell immunotherapies," said Dr. Henry Ji, Chairman and CEO of Sorrento. "Our partnership with KI combines our know-how with the expertise of a world-renowned institution in the field of NK cell therapy. These types of partnerships are essential in advancing medicine and bringing new solutions to cancer patients in need.”

KI scientists within NextGenNK will establish iPSC-derived NK-based therapeutic candidates utilizing Sorrento’s constructs and DAR technology. Work within KI has contributed to the development of methodologies that consistently generate robust and potent NK cell lineages following iPSC differentiation. Clinical trials of NK cell-based therapies for treatment of multiple myeloma led by researchers at KI have yielded promising preliminary results with long-lasting remissions. In a very cross-knit collaboration between Sorrento and KI, the team will aim to establish novel allogeneic, off-the-shelf, retargeted NK cell-based therapies.

Utilizing iPSCs enables mass production of off-the-shelf NK cell therapies that leverage Sorrento’s existing manufacturing infrastructure and know-how. Sorrento expects these validated re-engineered NK cell-based therapeutic candidates could potentially become a new generation in off-the-shelf treatments for cancer and infectious diseases. The core research will be performed at Karolinska Institutet with active involvement of the Sorrento R&D team in San Diego.

“The present collaboration brings together key competence from Sorrento and KI in an important area of cancer immunotherapy research. Sorrento’s intellectual contribution to the research at the Competence Center is a critical piece in enabling retargeted off-the-shelf NK cell products,” said Evren Alici, Principal Investigator at KI.

“This is an important step in further enabling academic and industrial partnerships in the mission of achieving common goals for advancement of novel cancer immunotherapies,” said Hans-Gustaf Ljunggren, Director of the NextGenNK Competence Center.
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva

loebas73
Premiummember
Premiummember
Berichten: 52
Lid geworden op: 03 feb 2021 11:26
waarderingen: 39

Re: Sorrento therapeutics

Bericht door loebas73 »

dochter123 liked last!

ancaoli
Forum elite
Forum elite
Berichten: 2200
Lid geworden op: 28 jan 2018 18:54
waarderingen: 1236

Re: Sorrento therapeutics

Bericht door ancaoli »

4PR’s op 1 week. Goe bezig 😁 Nu nog de koers...
Vaste Portefeuille:Recticel, WRN, Accentis, Global G, Roularta, Agfa, Ontex, OCI, Sorrento, Inventiva









Plaats reactie